Direct oral anticoagulants (DOACs) and parenteral direct ... | 合法醫療器材資訊網

Read More

2021年5月31日 — Anticoagulants are used for treating and preventing embolic events. The most common oral anticoagulatory agents are vitamin K antagonists ... Read More

由 E Altiok 著作 · 2018 · 被引用 19 次 — Oral anticoagulation therapy can prevent the majority of ischemic strokes in patients with atrial fibrillation (absolute risk reduction from 6.0% to 2.2%) and extend ... Read More

由 S Julia 著作 · 2017 · 被引用 39 次 — In recent years, four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban, have been compared with warfarin for stroke ... Read More

由 W Ageno 著作 · 2012 · 被引用 1557 次 — The antithrombotic effect of each oral anticoagulant drug, the interactions, and the monitoring of anticoagulation intensity are described in detail ... Read More

They are considered to be at least as effective as warfarin. Available medications in this category include apixaban (Eliquis®), betrixaban (BevyxXa®), dabigatran (​ ... Read More

2021年6月11日 — Warfarin continues to be the most widely used oral anticoagulant but the use of the newer oral anticoagulants (dabigatran etexilate, rivaroxaban, ... Read More

由 LLK Leung 著作 · 被引用 2 次 — Acronyms that have been created to refer to the orally acting direct thrombin inhibitors and direct factor Xa inhibitors together include direct oral anticoagulants ( ... Read More

由 R Hinojar 著作 · 2015 · 被引用 61 次 — New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (​VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Read More